Abstract 3073
Background
Approximately 40% of patients with node positive in axilla (N1) will have axillary pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). The application of sentinel lymph nodes (SNs) biopsy (SNB) following NAC for initially node-positive breast cancer is unclear because of high false-negative results in previous studies (SENTINA, ACOSOG Z1071). These trials, using blue dye (BD) and/or radioisotope (RI) agent, showed the diagnostic accuracy of SNB was closely related to the number of SNs. We presented the efficacy of indocyanine green (ICG) fluorescence navigation method for SNB in clinically node-negative (cN0) patients (ASCO2008). The fluorescent ICG method can provide higher number of SNs. Moreover, some reports showed that florescence SNs with metastases could not be identified by radioactivity. To determine the detection rate, the false-negative rate of SNs using the fluorescent ICG method after NAC for biopsy-proved N1 breast cancer retrospectively.
Methods
Of 2301 patients (January 2010 - March 2018), 135 women with N1 (fine needle aspiration or core needle biopsy proved) received NAC. Node status after NAC was evaluated by ultrasound findings: Group 1 (N1 converted ycN0, n = 105) and Group 2 (N1 remained ycN1, n = 30). All patients underwent SNB using both ICG- and BD-method and axillary lymph node dissection.
Results
The average number of SNs removed were Group 1 (ICG: 3.65, BD: 1.37), Group 2 (ICG: 2.99, BD: 0.93). Detection rate of SNs: Group 1 ICG 97.1% (95% CI 91.9-99.0, 102 of 105), BD 77.1% (95% CI 68.2-84.1, 81 of 105), Group 2 ICG 86.7% (95% CI 70.3-94.7, 26 of 30), BD 53.3% (95% CI 36.1-69.8, 16 of 30). Resulting of a false-negative rate: Group 1 ICG 7.69% (95% CI 2.65-20.3, 3 of 39), BD 35.7% (95% CI 20.7-54.2, 10 of 28), Group 2 ICG 11.5% (95% CI 4.00-29.0, 3 of 26), BD 18.8% (95% CI 6.59-43.0, 3 of 16). Axillary pCR was 46.7% (63 of 135).
Conclusions
In patients whose axillary nodal status converted from N1 to ycN0, the fluorescent ICG method with higher number detection of SNs showed a remarkable high detection rate and a low false-negative rate of SNs, compared with those of Blue dye which is one of conventional method.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract